BioCentury | Jan 26, 2015
Clinical News

VT-122HCC: Phase II data

...were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. Vicus Therapeutics LLC...
BioCentury | Jan 26, 2015
Clinical News

VT-122PC: Pilot trial data

...were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. Vicus Therapeutics LLC...
BioCentury | Aug 21, 2014
Cover Story

Fat chance for cancer cachexia

...antagonist activity Phase II Rose Pharma A/S GTP-200 Ghrelin-based compound Phase II GTP-300 Ghrelin peptide Vicus Therapeutics LLC...
BioCentury | Mar 7, 2011
Clinical News

VT-122: Phase II started

...Bayer and Onyx agreed to support the trial. Terms of the deal were not disclosed. Vicus Therapeutics LLC...
BioCentury | Jan 22, 2007
Clinical News

VT-122: Phase II start

...Vicus will begin an open-label, placebo-controlled, U.S. and Indian Phase II trial in 60 patients. Vicus Therapeutics LLC...
Items per page:
1 - 5 of 5
BioCentury | Jan 26, 2015
Clinical News

VT-122HCC: Phase II data

...were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. Vicus Therapeutics LLC...
BioCentury | Jan 26, 2015
Clinical News

VT-122PC: Pilot trial data

...were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. Vicus Therapeutics LLC...
BioCentury | Aug 21, 2014
Cover Story

Fat chance for cancer cachexia

...antagonist activity Phase II Rose Pharma A/S GTP-200 Ghrelin-based compound Phase II GTP-300 Ghrelin peptide Vicus Therapeutics LLC...
BioCentury | Mar 7, 2011
Clinical News

VT-122: Phase II started

...Bayer and Onyx agreed to support the trial. Terms of the deal were not disclosed. Vicus Therapeutics LLC...
BioCentury | Jan 22, 2007
Clinical News

VT-122: Phase II start

...Vicus will begin an open-label, placebo-controlled, U.S. and Indian Phase II trial in 60 patients. Vicus Therapeutics LLC...
Items per page:
1 - 5 of 5